Clinical trial
Effect of Methotrexate Discontinuation on Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Patients With Autoimmune Rheumatic Diseases
NCT07242092 is registered in ClinicalTrials.gov with University of Sao Paulo General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Methotrexate Discontinuation on Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Patients With Autoimmune Rheumatic Diseases
- Lead sponsor
- University of Sao Paulo General Hospital
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- June 22, 2026
- Completion date
- December 30, 2028
- Enrollment
- 192 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune rheumatic diseases